{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+empagliflozin", "query": { "intervention": "Placebo to empagliflozin" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 61, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+to+empagliflozin&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-03T14:20:36.581Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06935370", "title": "A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "vicadrostat", "type": "DRUG" }, { "name": "empagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4200, "start_date": "2025-05-20", "completion_date": "2029-02-22", "has_results": false, "last_update_posted_date": "2026-10-01", "last_synced_at": "2026-10-03T14:20:36.581Z", "location_count": 88, "location_summary": "Beverly Hills, California • Covina, California • Encinitas, California + 74 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Covina", "state": "California" }, { "city": "Encinitas", "state": "California" }, { "city": "Merced", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06935370" }, { "nct_id": "NCT02597049", "title": "A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "Dulaglutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "SGLT2 inhibitor", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 424, "start_date": "2015-11", "completion_date": "2017-02", "has_results": true, "last_update_posted_date": "2020-06-17", "last_synced_at": "2026-10-03T14:20:36.581Z", "location_count": 13, "location_summary": "Encino, California • Huntington Park, California • Los Angeles, California + 9 more", "locations": [ { "city": "Encino", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02597049" }, { "nct_id": "NCT06507657", "title": "Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hypertension", "Cardiovascular Diseases" ], "interventions": [ { "name": "empagliflozin", "type": "DRUG" }, { "name": "Placebo tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 80, "start_date": "2024-12-12", "completion_date": "2029-01-15", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-10-03T14:20:36.581Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06507657" }, { "nct_id": "NCT01167881", "title": "Efficacy and Safety of Empagliflozin (BI 10773) With Metformin in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "BI 10773", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1549, "start_date": "2010-08", "completion_date": "2015-08", "has_results": true, "last_update_posted_date": "2016-09-02", "last_synced_at": "2026-10-03T14:20:36.581Z", "location_count": 25, "location_summary": "Phoenix, Arizona • Hot Springs, Arkansas • Sacramento, California + 20 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Sacramento", "state": "California" }, { "city": "West Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01167881" }, { "nct_id": "NCT06260059", "title": "Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Adult Congenital Heart Disease", "Heart Failure" ], "interventions": [ { "name": "Empagliflozin 10 MG", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anita Saraf", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2024-09-17", "completion_date": "2027-06-01", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-03T14:20:36.581Z", "location_count": 3, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06260059" }, { "nct_id": "NCT00749190", "title": "BI 10773 add-on to Metformin in Patients With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "BI 10773", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "sitagliptin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 495, "start_date": "2008-08", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-06-13", "last_synced_at": "2026-10-03T14:20:36.581Z", "location_count": 19, "location_summary": "Chula Vista, California • Mission Viejo, California • Pasadena, California + 15 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Spring Valley", "state": "California" }, { "city": "Walnut Creek", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00749190" }, { "nct_id": "NCT06609356", "title": "Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Type 1 Diabetes Mellitus", "Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY)", "MODY2 Diabetes", "Healthy Volunteer" ], "interventions": [ { "name": "Study Visit 1", "type": "PROCEDURE" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Study Visit 2", "type": "PROCEDURE" }, { "name": "Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Vanderbilt University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 27, "start_date": "2025-07-03", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-10-03T14:20:36.581Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06609356" }, { "nct_id": "NCT03057977", "title": "EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "Empagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3730, "start_date": "2017-03-06", "completion_date": "2020-05-28", "has_results": true, "last_update_posted_date": "2021-05-18", "last_synced_at": "2026-10-03T14:20:36.581Z", "location_count": 92, "location_summary": "La Mesa, California • Long Beach, California • Los Angeles, California + 81 more", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Merced", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03057977" }, { "nct_id": "NCT01131676", "title": "BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME).", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "BI 10773 low dose", "type": "DRUG" }, { "name": "Placebo BI 10773 high dose", "type": "DRUG" }, { "name": "BI 10773 high dose", "type": "DRUG" }, { "name": "Placebo BI 10773 low dose", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7064, "start_date": "2010-07", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-16", "last_synced_at": "2026-10-03T14:20:36.581Z", "location_count": 170, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 140 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Little Rock", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01131676" }, { "nct_id": "NCT05726032", "title": "Empagliflozin in Patients With Cirrhosis and Ascites", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cirrhosis", "Liver Failure" ], "interventions": [ { "name": "Empagliflozin 10 MG", "type": "DRUG" }, { "name": "Matching Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-09-11", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-03T14:20:36.581Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT05726032" } ] }